The new generation of messenger RNA (mRNA) vaccines against influenza.
Eficacia vacunal
Flu
Gripe
Messenger RNA vaccines
Vaccine efficacy
Vacunas ARN mensajero
Journal
Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
25
05
2021
revised:
08
07
2021
accepted:
13
07
2021
medline:
8
5
2023
pubmed:
30
7
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines.
Identifiants
pubmed: 35906174
pii: S2529-993X(22)00166-6
doi: 10.1016/j.eimce.2022.07.006
pmc: PMC9315338
pii:
doi:
Substances chimiques
Influenza Vaccines
0
mRNA Vaccines
0
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-304Informations de copyright
Copyright © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.